Our Leaders Reflect on a Historic #ASCO22 for Daiichi Sankyo

The 2022 American Society of Clinical Oncology (ASCO22) Annual Meeting was highly anticipated across the entire oncology community as the first opportunity to share the latest innovations in cancer research, in-person, since the 2019 meeting. With over 200 sessions complementing this year’s meeting theme, “Advancing Equitable Cancer Care Through Innovation,” ASCO22 did not disappoint and will not soon be forgotten. The energy of the meeting was palpable as we reconnected and engaged with the global oncology community, bringing forward groundbreaking science in oncology with the potential to transform standards of care for patients around the world.

Aligned with a single mission of providing innovative treatments for patients with cancer, this year’s meeting brought out the best of scientific collaboration. For Daiichi Sankyo, ASCO22 was historic as we demonstrated our bold leadership in oncology with numerous advances across our ADC portfolio. Here’s what our leaders had to say about presenting our latest scientific advancements with such a prestigious group of global oncology innovators at ASCO22:

• “Following the presentation of our breast cancer data at the ASCO Plenary Session, I looked around to catch the reactions of thousands of ASCO attendees who were moved to give a standing ovation,” said Ken Keller, President and CEO of Daiichi Sankyo, Inc. and Global Head, Oncology Business. “It was incredible to watch people turn to one another in amazement, realizing how treating breast cancer could change.”

• Ken Takeshita, Global Head of R&D at Daiichi Sankyo said, “For Daiichi Sankyo, this year’s ASCO meeting was a proud moment for the entire organization and an incredibly historic moment for patients with breast cancer.”

• “With the important data in breast, lung, ovarian and renal cell cancer presented at ASCO, Daiichi Sankyo continues to work to change the way cancer is treated,” said Gilles Gallant, Global Head, Oncology Clinical Development. “Thousands of people around the world worked hard to produce the quality of data presented at the meeting, and we look forward to continue leveraging our science to deliver innovative medicines for patients with cancer.”

• “The future of oncology treatment for patients in my opinion can be described in two words—progress and promise,” said Mary Pinder-Schenck, Head of Global Oncology Medical Affairs. “We’ve seen data at ASCO 2022 that shows remarkable improvements over the standard of care.”

• “At this year’s ASCO, Daiichi Sankyo has demonstrated that we are a global leader in oncology,” said Dan Switzer, Head of US Oncology Business Division. “We must now continue to work together to deliver our medicines to people with cancer worldwide so no patient is left behind.”

What makes the ASCO Annual Meeting so unique is the collective impact we can achieve by innovating across boundaries to help increase access and improve clinical outcomes and quality of life for patients worldwide. At Daiichi Sankyo, we create practice changing solutions for the patients of today and tomorrow. The ability to share ground-breaking scientific data with the potential to impact patients with cancer worldwide, in-person at ASCO22, will forever be a special milestone for the entire Daiichi Sankyo organization.